HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$6.25 USD
+0.11 (1.79%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $6.19 -0.06 (-0.96%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOOK 6.25 +0.11(1.79%)
Will HOOK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HOOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOOK
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
HOOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for February 2nd
Other News for HOOK
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Buy Rating Affirmed for Hookipa Pharma Amidst Promising HB-200 Trial Results and Increased Market Launch Probability
Hookipa Pharma price target raised by $1 at H.C. Wainwright, here's why